304 related articles for article (PubMed ID: 36293366)
61. PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations.
Mansour MSI; Malmros K; Mager U; Ericson Lindquist K; Hejny K; Holmgren B; Seidal T; Dejmek A; Dobra K; Planck M; Brunnström H
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562908
[TBL] [Abstract][Full Text] [Related]
62. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
Gelatti ACZ; Cordeiro de Lima VC; Freitas H; Werutsky G; Gaiger AM; Klock C; Viola PP; Shiang C; de Macedo MP; Lopes LF; De Marchi P; Albino da Silva EC; Moura F; Borges G; Zaffaroni F; Nunes Filho PR; Araujo LH; Mascarenhas E; Mathias C; Barrios C; Zukin M
Clin Lung Cancer; 2020 Nov; 21(6):e511-e515. PubMed ID: 32389509
[TBL] [Abstract][Full Text] [Related]
63. Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with
Cho JH; Zhou W; Choi YL; Sun JM; Choi H; Kim TE; Dolled-Filhart M; Emancipator K; Rutkowski MA; Kim J
Cancer Res Treat; 2018 Jan; 50(1):95-102. PubMed ID: 28301925
[TBL] [Abstract][Full Text] [Related]
64. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
65. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Yang CY; Lin MW; Chang YL; Wu CT
Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
[TBL] [Abstract][Full Text] [Related]
66. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.
Lin K; Cheng J; Yang T; Li Y; Zhu B
Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):95-101. PubMed ID: 25998384
[TBL] [Abstract][Full Text] [Related]
67. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
68. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
[No Abstract] [Full Text] [Related]
69. Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.
Rivera MP; Charlot M; Durham DD; Throneburg A; Lane LM; Perera P; Samulski TD; Henderson LM
Chest; 2021 Sep; 160(3):1121-1130. PubMed ID: 33887243
[TBL] [Abstract][Full Text] [Related]
70. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma".
Shigeta N; Yokose T; Murakami S; Isaka T; Shinada K; Yoshioka E; Narita A; Katakura K; Kondo T; Kato T; Nagashima T; Saito H; Ito H
Thorac Cancer; 2024 Feb; 15(6):458-465. PubMed ID: 38197164
[TBL] [Abstract][Full Text] [Related]
71. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
[TBL] [Abstract][Full Text] [Related]
72. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
73. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
[TBL] [Abstract][Full Text] [Related]
74. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
75. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
76. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
[TBL] [Abstract][Full Text] [Related]
77. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
78. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
79. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
[TBL] [Abstract][Full Text] [Related]
80. [Comparative Study of PD-L1 Expression in Different Sites of
Non-small Cell Lung Cancer].
Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]